| SCHAEYBROECK, Van, S ROLFO, CD ELEZ, E KELLY, S HOULDEN, J COLLINS, L LOVE, S ANDRE, T LAWLER, M Di NICOLANTONIO, F GRAYSON, Vlad POPOVICI, VC BARDELLI, A LAURENT-PUIG, P SALTO-TELLEZ, M MAUGHAN, T TABERNERO, J PEETERS, M WILSON, RH MIDDLETON and MR. MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. Journal of clinical oncology. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, 2015, vol. 33, No 15, p. "Amer Soc Clin Oncol"-"0", 1 pp. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632. |
Other formats:
BibTeX
LaTeX
RIS
@article{1392213,
author = {Schaeybroeck, Van and Rolfo, S and Elez, CD and Kelly, E and Houlden, S and Collins, J and Love, L and Andre, S and Lawler, T and Nicolantonio, M Di and Grayson, F and Popovici, Vlad and Bardelli, VC and LaurentandPuig, A and SaltoandTellez, P and Maughan, M and Tabernero, T and Peeters, J and Wilson, M and Middleton, RH and MR, },
article_location = {2318 MILL ROAD, STE 800, ALEXANDRIA, VA},
article_number = {15},
doi = {http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632},
language = {eng},
issn = {0732-183X},
journal = {Journal of clinical oncology},
title = {MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.},
url = {http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632},
volume = {33},
year = {2015}
}
TY - JOUR
ID - 1392213
AU - Schaeybroeck, Van - Rolfo, S - Elez, CD - Kelly, E - Houlden, S - Collins, J - Love, L - Andre, S - Lawler, T - Nicolantonio, M Di - Grayson, F - Popovici, Vlad - Bardelli, VC - Laurent-Puig, A - Salto-Tellez, P - Maughan, M - Tabernero, T - Peeters, J - Wilson, M - Middleton, RH - MR,
PY - 2015
TI - MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
JF - Journal of clinical oncology
VL - 33
IS - 15
SP - "Amer Soc Clin Oncol"-"0"
EP - "Amer Soc Clin Oncol"-"0"
PB - AMER SOC CLINICAL ONCOLOGY
SN - 0732183X
UR - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632
L2 - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632
ER -
SCHAEYBROECK, Van, S ROLFO, CD ELEZ, E KELLY, S HOULDEN, J COLLINS, L LOVE, S ANDRE, T LAWLER, M Di NICOLANTONIO, F GRAYSON, Vlad POPOVICI, VC BARDELLI, A LAURENT-PUIG, P SALTO-TELLEZ, M MAUGHAN, T TABERNERO, J PEETERS, M WILSON, RH MIDDLETON and MR. MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. \textit{Journal of clinical oncology}. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, 2015, vol.~33, No~15, p.~''Amer Soc Clin Oncol''-''0'', 1 pp. ISSN~0732-183X. Available from: https://dx.doi.org/10.1200/jco.2015.33.15\_{}suppl.tps3632.
|
